Observational study shows varices increase bleeding risk in hepatocellular carcinoma patients, indicating proactive management may improve outcomes.
In unresectable HCC patients treated with atezolizumab plus bevacizumab, varices increase bleeding risk. However, proactive management and careful monitoring could mitigate their impact on OS and help increase the DCR.
No takes yet. Share an insight, caveat, or question.
Park et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: